CoChat

Neuroimaging-based biomarkers for treatment selection in major depressive disorder

Open access
Dunlop, Boadie W., Mayberg, Helen S. · 2014 · Dialogues in Clinical Neuroscience

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Abstract

The use of neuroimaging approaches to identify likely treatment outcomes in patients with major depressive disorder is developing rapidly. Emerging work suggests that resting state pretreatment metabolic activity in the fronto-insular cortex may distinguish between patients likely to respond to psychotherapy or medication and may function as a treatment-selection biomarker. In contrast, high metabolic activity in the subgenual anterior cingulate cortex may be predictive of poor outcomes to both medication and psychotherapy, suggesting that nonstandard treatments may be pursued earlier in the treatment course. Although these findings will require replication before clinical adoption, they provide preliminary support for the concept that brain states can be measured and applied to the selection of a specific treatment most likely to be beneficial for an individual patient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.31887/dcns.2014.16.4/bdunlop

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. (A) Scatterplot of pretreatment 2-[18F]-fluoro-2-deoxyD-glucose positron emission tomography (PET) metabolic activity in the anterior insular cortex of individual patients remitting (REM) and not responding (NR) to treatment with either escitalopram or cognitive behavioral therapy (CBT). Normalized metabolic activity in the anterior insula subdivided patients into hypermetabolic and hypometabolic subgroups. (B) Insula activity correlated with changes in the Hamilton Depression Rating Scale (HDRS) score in the full cohort of subjects treated with either CBT or escitalopram oxalate. From reference 28: McGrath CL, Kelley ME, Holtzheimer PE, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry. 2013:70:821-829.
Figure 1. (A) Scatterplot of pretreatment 2-[18F]-fluoro-2-deoxyD-glucose positron emission tomography (PET) metabolic activity in the anterior insular cortex of individual patients remitting (REM) and not responding (NR) to treatment with either escitalopram or cognitive behavioral therapy (CBT). Normalized metabolic activity in the anterior insula subdivided patients into hypermetabolic and hypometabolic subgroups. (B) Insula activity correlated with changes in the Hamilton Depression Rating Scale (HDRS) score in the full cohort of subjects treated with either CBT or escitalopram oxalate. From reference 28: McGrath CL, Kelley ME, Holtzheimer PE, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry. 2013:70:821-829.CC BY-NC-ND · PubMed Central
Figure 2 (A) Percent change in the Hamilton Depression Rating Scale (HDRS) after 12 weeks of treatment with either escitalopram or cognitive behavioral therapy (CBT) correlated with pretreatment metabolic activity in the subcallosal cingulate cortex (SCC) and superior temporal sulcus (STS). (B) Percentage change in HDRS correlated with pretreatment SCC and STS metabolic activity among patients completing 12 weeks of monotherapy followed by 12 weeks of combination escitalopram plus CBT. From reference 65: McGrath CL, Keliey ME, Dunlop BW, Holtzheimer PE, Craighead WE, Mayberg HS. Pretreatment brain states identify likely nonresponse to standard treatments for depression. Biol Psychiatry. 2014:76:527-535.
Figure 2 (A) Percent change in the Hamilton Depression Rating Scale (HDRS) after 12 weeks of treatment with either escitalopram or cognitive behavioral therapy (CBT) correlated with pretreatment metabolic activity in the subcallosal cingulate cortex (SCC) and superior temporal sulcus (STS). (B) Percentage change in HDRS correlated with pretreatment SCC and STS metabolic activity among patients completing 12 weeks of monotherapy followed by 12 weeks of combination escitalopram plus CBT. From reference 65: McGrath CL, Keliey ME, Dunlop BW, Holtzheimer PE, Craighead WE, Mayberg HS. Pretreatment brain states identify likely nonresponse to standard treatments for depression. Biol Psychiatry. 2014:76:527-535.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Research works printed but not linked: 7

  1. Uher R., Am J Psychiatry. 2014 Jul 14. Epub ahead of print.
  2. Fu CH., 2012, Neurobiol Dis., 52, 75
  3. American Psychiatric Association., Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
  4. Konarski JZ., 2009, J Psychiatry Neurosci., 34, 175
  5. Dunlop BW., J Neuropsychiatry Clin Neurosci. 2014. In press.
  6. Samson AC., 2011, J Psychiatr Res., 35, 1214
  7. Frodl T., 2008, J Psychiatry Neurosci., 33, 423

Cited by

See all 127

Metadata

Authors
Dunlop, B. W., & Mayberg, H. S.
Affiliations
Emory University (US)
Corresponding author
Dunlop, Boadie W.
Venue
Dialogues in Clinical Neuroscience
Published
2014-12-31
Volume
16
Issue
4
Pages
479-490
ISSN
  • 1294-8322 (ISSN-L)
  • 1958-5969
OpenAlex
W202043522
Cited by
127
References
75
Citations by year
2026: 7 · 2025: 10 · 2024: 8 · 2023: 7 · 2022: 7 · 2021: 9 · 2020: 15 · 2019: 12 · 2018: 14 · 2017: 16 · 2016: 15 · 2015: 5
FWCI
8.75
Type
journal article
Language
en
Open access
Locations
  • Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (R01MH073719)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Functional Brain Connectivity Studies
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
major depressive disorder, treatment selection, neuroimaging biomarkers, subgenual anterior cingulate cortex, treatment response prediction, psychotherapy, antidepressants, personalized treatment
MeSH terms
Antidepressive Agents, Brain, Depressive Disorder, Major, Major Depressive Disorder, Humans, Biomarkers, Precision Medicine, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuroimaging-based biomarkers for treatment selection in major depressive disorder. https://app.cochat.ai/papers/10.31887/dcns.2014.16.4/bdunlop
The paper
Dunlop, B. W., & Mayberg, H. S. (2014). Neuroimaging-based biomarkers for treatment selection in major depressive disorder. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2014.16.4/bdunlop

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.